signumia
Data is being collected. The dashboard will appear when it is available.
SYMBOL
Data is being collected. The dashboard will appear when it is available.
DVA

Close price

$213.04

Latest price

$213.07

Change vs close

+0.01%

Current price: $213.07

Market cap

13.68B

Pre-market and after-hours data may be partial or delayed depending on the source and licensing.

DaVita Inc.

DVA

NYSE · Health Care · Misc Health and Biotechnology Services

Company Profile

DaVita (NYSE: DVA) is a healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey - from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of March 31, 2026, DaVita served approximately 296,300 patients at 3,262 outpatient dialysis centers, of which 2,666 centers were located in the United States and 596 centers were located in 14 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere.

Website

https://www.davita.com

Country

CO

Sector

Health Care

Industry

Misc Health and Biotechnology Services

CIK

0000927066

Candlestick Chart

1D · Data source: loading

Loading candle data

Quarterly Performance Snapshot

Actual revenue and net income based on quarterly filings

Q2 Aug 2026

Quarterly Snapshot

Q2 Aug 2026

Mix

17.46B

Market cap

78.35%

13.68B

Expected quarterly revenue

20.23%

3.53B

Estimated quarterly net income

1.43%

249.21M

Market cap / expected revenue

3.87x

Revenue

Forecast

3.53B

Previous quarter

+3.39%

Net income

Forecast

249.21M

Previous quarter

+26.16%

Revenue and Net Income Trend

RevenueNet income

Quarterly Performance

13 quarters

Financial Statements

SEC Filings

12 filings shown

Open the original SEC filings to view the full document.

FormFiling DateReport DateAccessionLink
4Jun 17, 2026Jun 15, 20260000927066-26-000099Document
4Jun 17, 2026Jun 15, 20260000927066-26-000098Document
11-KJun 17, 2026Dec 31, 20250000927066-26-000096Document
144Jun 16, 2026No data0001969223-26-000708Document
144Jun 15, 2026No data0001969223-26-000702Document
144Jun 15, 2026No data0001969223-26-000701Document
144Jun 15, 2026No data0001969223-26-000693Document
8-KJun 8, 2026Jun 4, 20260001206774-26-000316Document
4May 28, 2026May 26, 20260000927066-26-000088Document
4May 18, 2026May 15, 20260000927066-26-000085Document
4May 18, 2026May 15, 20260000927066-26-000084Document
4May 18, 2026May 15, 20260000927066-26-000083Document

Latest News

12 articles
ZacksJun 24, 2026, 12:00 AMnasdaq

DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.

Open article
ZacksJun 24, 2026, 12:00 AMnasdaq

DaVita Stock Benefits From Expanding Community-Based Kidney Care

DVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.

Open article
ZacksJun 23, 2026, 12:00 AMnasdaq

DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

Open article
ZacksJun 22, 2026, 12:00 AMnasdaq

3 Medical Stocks to Bet on Amid Market Optimism Following SpaceX IPO

Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.

Open article
ZacksJun 22, 2026, 12:00 AMnasdaq

Best Growth Stocks to Buy for June 22nd

HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 22nd, 2026.

Open article
ZacksJun 22, 2026, 12:00 AMnasdaq

Zacks.com featured highlights include Murphy, DaVita, Hewlett Packard and Vishay

Murphy, DaVita, Hewlett Packard and Vishay have been highlighted in this Screen of The Week article.

Open article
ZacksJun 18, 2026, 12:00 AMnasdaq

DaVita HealthCare (DVA) Stock Dips While Market Gains: Key Facts

DaVita HealthCare (DVA) closed the most recent trading day at $207.91, moving 1.27% from the previous trading session.

Open article
ZacksJun 17, 2026, 12:00 AMnasdaq

DaVita Expands Specialized Care Beyond Acute Settings Through IKC

DVA is expanding kidney care beyond hospitals with IKC, digital tools and AI to improve coordination, lower costs and support patients.

Open article
The Motley FoolJun 15, 2026, 12:00 AMnasdaq

DaVita vs. Encompass Health: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsDaVita operates more than 3,200 dialysis centers globally, serving roughly 295,000 patients with a dominant market share in kidney care.

Open article
ZacksJun 15, 2026, 12:00 AMnasdaq

Best Growth Stocks to Buy for June 15th

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 15, 2026.

Open article
ZacksJun 11, 2026, 12:00 AMnasdaq

DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, DaVita HealthCare (DVA) closed at $203.83, indicating a +2.66% shift from the previous trading day.

Open article
ZacksJun 11, 2026, 12:00 AMnasdaq

DaVita HealthCare (DVA) Moves to Strong Buy: Rationale Behind the Upgrade

DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Open article